Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

NCT07037199 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University